0
2021
Breast Cancer Liquid Biopsy Market

Breast Cancer Liquid Biopsy Market

by Product & Service (Reagent Kits, Instruments, and Services), Circulating Biomarker (Circulating Tumor Cells, Extracellular Vesicles, and Circulating Tumor DNA), and Application (Diagnostics, Prognostics, and Risk Assessment): Global Opportunity Analysis and Industry Forecast, 2019-2027
Update Available On-Demand

Report Code: A07618
Pages: 305
Feb 2021 | 3570 Views
Author(s) : Sagar M, Sushant T , Onkar S
Tables: 187
Charts: 51
  • Formats*:

  • Single User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • It comes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Breast Cancer Liquid Biopsy Market

Request Now !

The global breast cancer liquid biopsy market size was valued at $87,641 thousand in 2019, and is projected to reach $357,051 thousand by 2027, registering a CAGR of 19.2% from 2019 to 2027.

The breast cancer liquid biopsy is a noninvasive alternative technique that makes use of blood as a sample and is chosen more than surgical tissue biopsy. There are various biomarkers that are used as a tool for detection of breast cancer such as circulating tumor cells (CTC), extracellular vesicles, and circulating tumor DNA. Breast cancer liquid biopsy aids to monitor progression of breast cancer disease based on heterogeneity of tumor cells in advanced stages of breast cancer. Moreover, breast cancer liquid biopsy test detects epidermal growth factor receptor (EGFR) gene mutations that support clinicians to choose the right breast cancer treatment at the right time.

Breast-Cancer-Liquid-Biopsy-Market,-2019-2027

Rise in prevalence of breast cancer, increase in demand for non-invasive breast cancer treatment, technological advancements in breast cancer liquid biopsy, availability of funding for liquid biopsy R&D, and increase in breast cancer liquid biopsy reagent approvals are the major factors that drive growth of the breast cancer liquid biopsy market. In addition, increase in patient awareness toward breast cancer treatment, advantages of breast cancer liquid biopsy tests over traditional tests, rise in adoption of liquid biopsy tests, surge in pre-screening programs for breast cancer detection, easy accessibility and high adoption of polymerase chain reaction (PCR) and next-generation sequencing (NGS) among healthcare professionals, and surge in demand for breast cancer liquid biopsy reagent kits are some other factors that contribute toward growth of the market. However, limitations associated with liquid biopsy testing and lack of access and awareness regarding breast cancer liquid biopsy in underdeveloped countries are expected to hinder growth of the market.  

The World Health Organization (WHO) on January 30, 2020 declared COVID-19 outbreak a public health emergency of international concern. COVID-19 has affected around 210 countries across the globe. The breast cancer liquid biopsy manufacturing and distributing companies have been affected by COVID-19 to a limited extent, owing to shutdowns in various COVID-19 affected countries and rise in number of healthcare workers falling ill in the wake of the COVID-19 pandemic, leading to short supply.

Breast Cancer Liquid Biopsy Market Segmentation  

The global breast cancer liquid biopsy market is segmented on the basis of product & service, circulating biomarker, application, and region. By product & service, the market is categorized into reagent kits, instruments, and services. By circulating biomarker, it is segregated into circulating tumor cells, extracellular vesicles, and circulating tumor DNA. Depending on application, it is classified into diagnostics, prognostics, and risk assessment. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Breast Cancer Liquid Biopsy Market
By Product & Service

Your browser does not support the canvas element.

Reagent Kit segment holds a dominant position in 2019 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Segment review 

Presently, on the basis of product & service, the reagent kits is the major revenue contributor, and is projected to grow significantly during the forecast period. Increase in number of breast cancer liquid biopsy test procedures, surge in demand for reagent kits, increase in breast cancer liquid biopsy reagent kit approvals, and advent of novel liquid biopsy reagents that execute circulating biomarker analysis and target enrichment are the key factors that boost growth of the segment.

Depending on application, the diagnostics segment is the major shareholder in the global breast cancer liquid biopsy market, owing to technological advancements in liquid biopsy systems, and increase in patient awareness toward safe and non-invasive liquid biopsy testing procedures. Moreover, rise in trend of developing personalized therapeutics and increase in number of patients suffering from breast cancer across the globe are other factors that contribute toward growth of the market.

Breast Cancer Liquid Biopsy Market
By Application

Your browser does not support the canvas element.

Diagnostics segment is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

Snapshot of Asia-Pacific breast cancer liquid biopsy market  

Asia-Pacific presents lucrative opportunities for key players operating in the breast cancer liquid biopsy market, owing to increase in number of patients suffering from breast cancer, increase in public awareness toward breast cancer liquid biopsy procedures, development of the R&D sector; rise in healthcare reforms; and increase in adoption of breast cancer liquid biopsy. Moreover, increase in demand for breast cancer liquid biopsy reagent kits, and rise in preference for noninvasive test procedures contribute toward growth of the market. Furthermore, surge in focus of leading manufacturers on expanding their geographical presence in emerging Asia-Pacific countries to capture high market share is expected to drive growth of the breast cancer liquid biopsy market in the region.

The key players profiled in this report include Biocept, Inc., F. Hoffmann-La Roche Ltd. (Foundation Medicine, Inc.), Fluxion Biosciences, Inc., Menarini Group (Menarini Silicon Biosystems, Inc.), Myriad Genetics, Inc., NeoGenomics Laboratories, Inc., Qiagen N.V., Sysmex Corporation, and Thermo Fisher Scientific Inc.

Breast Cancer Liquid Biopsy Market
By Region

2027
North America 
Europe
Asia-pacific
Lamea

Asia-Pacific region would exhibit the highest CAGR of 20.1% during 2019-2027.

Get more information on this report : Request Sample Pages

Key Benefits For Stakeholders

  • The study provides an in-depth analysis of the breast cancer liquid biopsy market size along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers breast cancer liquid biopsy market analysis from 2019 to 2027, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
  • A comprehensive analysis of four regions is provided to determine the prevailing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook and global breast cancer liquid biopsy market growth.

Breast Cancer Liquid Biopsy Market Report Highlights

Aspects Details
By Product Services
  • Reagent Kits
  • Instruments
  • Services
By Circulating Biomarker
  • Circulating Tumor Cells
  • Extracellular Vesicles
  • Circulating Tumor DNA
By Application
  • Diagnostics
  • Prognostics
  • Risk assessment
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, France, UK, Italy, Spain, Rest of Europe)
  • Asia-Pacific  (Japan, China, India, Rest of Asia-Pacific)
  • LAMEA  (Latin America, Middle East, Africa)
Key Market Players BIOCEPT INC., F. HOFFMANN-LA ROCHE LTD. (FOUNDATION MEDICINE, INC.), FLUXION BIOSCIENCES, INC., MENARINI GROUP (MENARINI SILICON BIOSYSTEMS, INC.), MYRIAD GENETICS, INC., NEOGENOMICS LABORATORIES, INC., QIAGEN N.V., SYSMEX CORPORATION, THERMO FISHER SCIENTIFIC, INC., GUARDANT HEALTH, INC.
 

Loading Table Of Content...


 
 

Breast cancer liquid biopsy tests have gained popularity as a simple, efficient, non-invasive alternative to solid tissue biopsies for breast cancer treatment. Moreover, breast cancer liquid biopsy tests are used for diagnostic and molecular characterization of tumor fragments and agents released in blood of breast cancer patients.

Rise in prevalence of breast cancer, surge in demand for breast cancer liquid biopsy reagent kits, rise in R&D activities and product innovations, and surge in pre-screening programs for breast cancer detection are expected to drive growth of the breast cancer liquid biopsy market. Moreover, increase in awareness among the population regarding breast cancer, rise in adoption of liquid biopsy tests, and rise in need for prognostic and diagnostic tests propel the market growth. However, limitations associated with liquid biopsy testing and lack of access and awareness regarding breast cancer liquid biopsy in underdeveloped countries are expected to hinder growth of the market.

North America is expected to remain dominant during the forecast period, owing to increase in demand for breast cancer liquid biopsy, rise in prevalence of breast cancer, and presence of major key players along with R&D centers. Moreover, Asia-Pacific and LAMEA are expected to offer lucrative opportunities to key players during the forecast period, owing to increase in patient awareness toward breast cancer treatment.
 

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com
 
FREQUENTLY ASKED QUESTIONS?

A. Rise in prevalence of breast cancer, increase in preference for noninvasive procedures, technological advancements in breast cancer liquid biopsy instruments, advantages of over solid tumor biopsy, and increase in patient awareness toward minimally invasive breast cancer liquid biopsy procedures are the key factors that fuel growth of the breast cancer liquid biopsy market. In addition, rise in funding for breast liquid biopsy R&D, favorable initiatives undertaken by governments and global health organizations, and increase in breast cancer liquid biopsy reagents approvals are another factor that contributes toward the growth of the market

A. Asia-Pacific has the highest growth rate in the market which is growing due to the contribution of the following emerging countries such as India with a CAGR of 21.7%. This is due to increase in preference for noninvasive procedures, technological advancements to detect breast cancer at early stage, increase in government initiatives to surge awareness about genome-based diagnostic procedures, and high adoption of polymerase chain reaction (PCR) and next-generation sequencing (NGS) among healthcare professionals.

A. Top companies such as F. Hoffmann-La Roche Ltd. (Foundation Medicine, Inc.), Biocept Inc., Menarini Group (Menarini Silicon Biosystems, Inc.), Qiagen N.V., Myriad Genetics, Inc., and NeoGenomics Laboratories, Inc. held a high market position in 2019. These key players held a high market postion owing to the strong geographical foothold in different regions.

A. Reagent kits segment is the most influencing segment owing to advent of novel liquid biopsy reagents that execute circulating biomarker analysis and target enrichment; increase in breast cancer liquid biopsy reagent kits approvals; and increase in funding for breast cancer liquid biopsy R&D are anticipated to drive the growth of the market. In addition, surge in demand for reagent kits, rise in number of breast cancer liquid biopsy test procedures, and increase in prevalence of breast cancer across the globe are other factors that contribute toward growth of the market.

A. The total market value of Breast Cancer Liquid Biopsy market is $87,640.8 thousand in 2019.

A. The forcast period for Breast Cancer Liquid Biopsy market is 2019 to 2027

A. The market value of Breast Cancer Liquid Biopsy market in 2020 is $83,468.5 thousand .

A. The base year is 2019 in Breast Cancer Liquid Biopsy market

A. Breast cancer liquid biopsy is a non-invasive blood test that detects tumor DNA fragments and circulating tumor cells (CTCs), which are released into the blood from primary tumors and metastatic sites

A. Breast cancer liquid biopsy provides a real-time method for treatment of breast cancer. It is used for collection & analysis of a blood sample taken from patients. It analyses the presence of tumor cell-derived biomarkers such as circulating tumor cells, extracellular vesicles, and circulating tumor DNA.

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Request Free Sample
RELATED TAGS

Purchase Full Report of
Breast Cancer Liquid Biopsy Market

Start reading instantly.
This Report and over 19,267+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,712
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
    (Feb 2022 - Feb 2023)
  • Data Pack
  • $4,125
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Feb 2022 - Feb 2023)
  • Single User
  • $5,769
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Feb 2022 - Feb 2023)
  • Five Users
  • $6,929
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Feb 2022 - Feb 2023)
  • Enterprise
    License/PDF

  • $10,663
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Feb 2022 - Feb 2023)
  • Library
    Membership

  • $ 999
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers